

### Results in Brief

	Six Months Ended 30 Sep 23 NZ\$M (except as otherwise stated)	Six Months Ended 30 Sep 24 NZ\$M (except as otherwise stated)	% Change (Reported)	% Change (Constant Currency <sup>1</sup> )
<b>FINANCIAL PERFORMANCE</b>				
<b>Total operating revenue</b>	<b>803.7</b>	<b>951.2</b>	<b>+18%</b>	<b>+17%</b>
Cost of sales	(317.6)	(362.5)	+14%	+12%
Gross profit	486.1	588.7	+21%	+21%
Gross margin	60.5%	61.9%	+141 bps	+198 bps
Selling, general and administrative expenses	(236.6)	(260.5)	+10%	+10%
Research and development expenses	(96.9)	(110.1)	+14%	+14%
R&D percentage of operating revenue	12.1%	11.6%	-48 bps	-39 bps
<b>Total operating expenses</b>	<b>(333.5)</b>	<b>(370.6)</b>	<b>+11%</b>	<b>+11%</b>
Operating profit before financing costs	152.6	218.1	+43%	+46%
Operating margin	19.0%	22.9%	+394 bps	+420 bps
Net financing expense	(12.0)	(11.7)	-3%	-58%
Profit before tax	140.6	206.4	+47%	+52%
Tax expense	(33.3)	(53.2)	+60%	+58%
<b>Profit after tax</b>	<b>107.3</b>	<b>153.2</b>	<b>+43%</b>	<b>+51%</b>
Effective tax rate	<b>23.7%</b>	<b>25.8%</b>		
Effective tax rate excluding R&D tax credit	<b>29.9%</b>	<b>30.1%</b>		

#### Revenue by Region:

North America	366.2	444.9	+21%
Europe	207.5	248.8	+20%
Asia Pacific	179.8	205.1	+14%
Other	50.2	52.4	+4%
<b>Total</b>	<b>803.7</b>	<b>951.2</b>	<b>+18%</b>

#### Revenue by Product Group:

Hospital	487.5	591.4	+21%
Homecare	314.4	359.4	+14%
Core products sub-total	801.9	950.8	+19%
Distributed and other	1.8	0.4	-78%
<b>Total</b>	<b>803.7</b>	<b>951.2</b>	<b>+18%</b>

	As at 31 Mar 24 NZ\$M (except as otherwise stated)	As at 30 Sep 24 NZ\$M (except as otherwise stated)	
<b>FINANCIAL POSITION</b>			
Tangible assets	2,100.8	2,259.4	+8%
Intangible assets <sup>2</sup>	180.9	176.0	-3%
Total assets	2,281.7	2,435.4	+7%
Total liabilities	(522.6)	(505.6)	-3%
<b>Shareholders' equity</b>	<b>1,759.1</b>	<b>1,929.8</b>	<b>+10%</b>
Gearing	1.8%	-2.9%	-256%
Net tangible asset backing (cents per share)	271	305	+13%

<sup>1</sup> Constant currency (CC) removes the impact of exchange rate movements. This approach is used to assess the Group's underlying comparative financial performance without any impact from changes in foreign exchange rates. The company's constant currency framework can be found on the company's website at [www.fphcare.com/ccf](http://www.fphcare.com/ccf). The reconciliation to reported results is included within the Financial Commentary section of the Interim Report.

<sup>2</sup> Includes Intangible and deferred tax assets.

## Results in Brief (continued)

	Six Months Ended 30 Sep 23 NZ\$M (except as otherwise stated)	Six Months Ended 30 Sep 24 NZ\$M (except as otherwise stated)	% Change
<b>CASH FLOWS</b>			
Net cash flow from operating activities	156.5	233.0	+49%
Net cash flow from investing activities	(275.5)	(55.1)	-80%
Net cash flow from financing activities	66.0	(137.2)	-308%
<b>SHARES OUTSTANDING</b>			
Weighted average basic shares outstanding	580,581,693	584,954,554	
Weighted average diluted shares outstanding	584,542,333	589,385,621	
Basic shares outstanding at period end	582,012,620	586,112,745	
<b>DIVIDENDS AND EARNINGS PER SHARE</b>			
Dividends per share (cents) – declared	18.0	18.5	+3%
Basic earnings per share (cents)	18.5	26.2	+42%